Australia - englanti - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin acetate, quantity: 100 microgram (equivalent: desmopressin, qty 89 microgram) - tablet, uncoated - excipient ingredients: potato starch; lactose monohydrate; magnesium stearate; povidone - adin tablets are indicated for the treatment of: cranial diabetes insipidus; primary nocturnal enuresis, in patients from 6 years of age with normal ability to concentrate urine, who are refractory to an enuresis alarm, or in whom an enuresis alarm is contraindicated or inappropriate.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin acetate, quantity: 200 microgram (equivalent: desmopressin, qty 178 microgram) - tablet, uncoated - excipient ingredients: lactose monohydrate; potato starch; magnesium stearate; povidone - adin tablets are indicated for the treatment of: cranial diabetes insipidus; primary nocturnal enuresis, in patients from 6 years of age with normal ability to concentrate urine, who are refractory to an enuresis alarm, or in whom an enuresis alarm is contraindicated or inappropriate.

Etelä-Afrikka - englanti - South African Health Products Regulatory Authority (SAHPRA)

pharmacare limited û woodmead - tablet - see ingredients - each tablet contains furosemide 40 mg

Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - furosemide, quantity: 500 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; lactose monohydrate; silicon dioxide; maltodextrin - indications as at 01 jan 1991 : frusemide in a high-dosage formulation such as urex forte ( 500 mg tablets ) is intended exclusively for patients with severely impaired renal function. for use under strict medical supervision only within a hospital setting (see dosage and administration). high doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure, e.g. in the post-operative phase and in association with septic infections; in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function e.g. in chronic glomerulonephritis, lupus erythematous and kimmelstiel-wilson syndrome. if diuresis is less than 2.5 l / day dialysis has to be used.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - furosemide, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch - indications as at 01 jan 1991 : oedema : in adults, infants and children frusemide is indicated for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver, renal disease including nephrotic syndrome and other oedematous states amenable to diuretic therapy. hypertension : may also be used alone in the control of mild to moderate hypertension and in combination with other antihypertensive agents in the treatment of more severe cases. studies have shown that frusemide is either less effective than or equally effective as thiazide diuretics in uncomplicated hypertension. however, in patients with severe renal function impairment, a diuretic and antihypertensive response to frusemide may be achieved while thiazides have no effect.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

arrow pharma pty ltd - furosemide, quantity: 40 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch - indications as at 01 jan 1991 : oedema : in adults, infants and children frusemide is indicated for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver, renal disease including nephrotic syndrome and other oedematous states amenable to diuretic therapy. hypertension : may also be used alone in the control of mild to moderate hypertension and in combination with other antihypertensive agents in the treatment of more severe cases. studies have shown that frusemide is either less effective than or equally effective as thiazide diuretics in uncomplicated hypertension. however, in patients with severe renal function impairment, a diuretic and antihypertensive response to frusemide may be achieved while thiazides have no effect.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lithium carbonate, quantity: 450 mg - tablet, modified release - excipient ingredients: povidone; maize starch; gelatin; titanium dioxide; magnesium stearate; macrogol 6000; carmellose calcium; lactose monohydrate; calcium behenate; purified talc; basic butylated methacrylate copolymer - lithium is indicated in the treatment of acute episodes of mania and hypomania and for the prophylaxis of recurrent manic-depressive illness.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - chlortalidone, quantity: 25 mg - tablet, uncoated - excipient ingredients: purified talc; iron oxide yellow; iron oxide red; colloidal anhydrous silica; lactose monohydrate; maize starch; magnesium stearate - indications as at 19 november 1996: essential arterial hypertension, as long as creatinine clearance is >30 ml/min; as primary therapy or in combination with other antihypertensive agents; stable, chronic heart failure of mild to moderate degree (functional class ii, iii), as long as creatinine clearance is >30ml/min; ascites due to cirrhosis of the liver in stable patients under close control.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - indapamide hemihydrate, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; maize starch; magnesium stearate; hypromellose; sodium lauryl sulfate; titanium dioxide; indigo carmine; iron oxide red; erythrosine; macrogol 400 - management of essential hypertension. it may be tried as the sole therapeutic agent in the treatment of mild to moderate hypertension. normally indapamide is used as the initial agent in multiple drug regimens.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: hypromellose; iron oxide black; macrogol 6000; colloidal anhydrous silica; lactose monohydrate; titanium dioxide; croscarmellose sodium; purified talc; microcrystalline cellulose; hyprolose; iron oxide red; magnesium stearate - irbesartan/hct sandoz is indicated for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.